Perampanel - Eisai

Drug Profile

Perampanel - Eisai

Alternative Names: E-2007; ER-155055-90; Fycompa

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ESTEVE
  • Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Seizures
  • Phase II Epilepsy
  • Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 31 May 2018 Perampanel receives priority review status for Partial epilepsies and Tonic-clonic seizures (Adjunctive treatment, Monotherapy, In children) in USA
  • 31 May 2018 The US FDA sets PDUFA date of September 28, 2018 for sNDA review for Partial epilepsies and Tonic-clonic seizures (Adjunctive treatment, Monotherapy, In children)
  • 31 May 2018 US FDA accepts sNDA for perampanel for Partial epilepsies and Tonic-clonic seizures (Adjunctive treatment, Monotherapy, In children) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top